Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.

Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.

Item
http://www.wikidata.org/entity/Q36822253
Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV InfectionThe use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza.A systems genetics approach provides a bridge from discovered genetic variants to biological pathways in rheumatoid arthritis.Natural anti-CCR5 antibodies in HIV-infection and -exposureClinical use of CCR5 inhibitors in HIV and beyondCCR5: From Natural Resistance to a New Anti-HIV Strategy.Role of eotaxin-1 signaling in ovarian cancerIdentification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation.CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination.
P2860

Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.

Item
http://www.wikidata.org/entity/Q36822253
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Assessing theoretical risk and ...... pment programme for maraviroc.
@en
type
label
Assessing theoretical risk and ...... pment programme for maraviroc.
@en
prefLabel
Assessing theoretical risk and ...... pment programme for maraviroc.
@en
P1433
P1476
P2093
P304
P31
P433
P478
P577
P698
P1433
P1476
Assessing theoretical risk and ...... opment programme for maraviroc
@en
P2093
P304
P31
P433
P478
P577
P698